# Rybrevant Faspro is approved across all indications of intravenously administered Rybrevant.

*biotech · news · 2025-12-23 · Medical Xpress*

## Key points

- Rybrevant Faspro is the first subcutaneous therapy for EGFR-mutated NSCLC approved by the FDA.
- The treatment reduces administration time from several hours to five minutes compared to intravenous Rybrevant.
- Subcutaneous Rybrevant Faspro reduces administration-related reactions fivefold versus intravenous administration.
- Rybrevant Faspro showed a lower incidence of venous thromboembolism than intravenous Rybrevant in clinical trials.
- Rybrevant Faspro is now approved across all indications of intravenously administered Rybrevant.

**Companies:** Johnson & Johnson
**Countries:** United States

[Read the full story on Medical Xpress](https://medicalxpress.com/news/2025-12-fda-subcutaneous-drug-egfr-mutated.html)

---

Canonical: https://newsio.io/n/b0288024-46cc-4202-a30a-27a936534d9c/rybrevant-faspro-is-approved-across-all-indications-of-intravenously-administere
Summarized by Newsio from Medical Xpress. https://newsio.io/how-it-works